JAMP-LISINOPRIL TABLET

Country: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

LISINOPRIL (LISINOPRIL DIHYDRATE)

Доступно од:

JAMP PHARMA CORPORATION

АТЦ код:

C09AA03

INN (Међународно име):

LISINOPRIL

Дозирање:

10MG

Фармацеутски облик:

TABLET

Састав:

LISINOPRIL (LISINOPRIL DIHYDRATE) 10MG

Пут администрације:

ORAL

Јединице у пакету:

100/500

Тип рецептора:

Prescription

Терапеутска област:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Резиме производа:

Active ingredient group (AIG) number: 0121550001; AHFS:

Статус ауторизације:

APPROVED

Датум одобрења:

2011-01-24

Карактеристике производа

1
_Pr_
_JAMP-Lisinopril (Lisinopril Tablets USP) Product Monograph _
PRODUCT MONOGRAPH
PR
JAMP-LISINOPRIL
Lisinopril Tablets USP
Tablets 5 mg, 10 mg and 20 mg lisinopril (as lisinopril dihydrate)
Angiotensin Converting Enzyme Inhibitor
JAMP Pharma Corporation
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
Date of Revision:
NOV 08, 2022
Submission Control Number: 268555
2
_Pr_
_JAMP-Lisinopril (Lisinopril Tablets USP) Product Monograph _
PRODUCT MONOGRAPH
PR
JAMP-LISINOPRIL
Lisinopril Tablets USP
Tablets 5 mg, 10 mg and 20 mg
Angiotensin Converting Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
Lisinopril is an angiotensin converting enzyme (ACE) inhibitor which
is used in
the treatment of
hypertension, congestive heart failure and following myocardial
infarction in
hemodynamically stable
patients.
ACE is a peptidyl dipeptidase which catalyzes the conversion of
angiotensin I to the pressor substance,
angiotensin II. Inhibition of ACE results in decreased plasma
angiotensin II, which
leads to increased
plasma renin activity (due to removal of negative feedback of renin
release)
and decreased aldosterone
secretion. Although the latter decrease is small, it results in a
small
increase in serum potassium. In
patients treated with JAMP-Lisinopril and a thiazide diuretic there
was essentially no change in serum
potassium (see PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a potent
vasodilator peptide. However, the role that this plays in the
therapeutic
effects of lisinopril is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be
primarily the
suppression of the renin-angiotensin-aldosterone system (RAAS),
lisinopril also lowers blood pressure
in patients with low-renin hypertension.
PHARMACODYNAMICS
Hypertension
_Adults: _Administration of lisinopril to patients with hypertension
results in a reduction of both supine
and
standing blood pressure. Abrupt withdrawal of lisinopril has not been
associated with a